This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	Acid phosphatase 5 tartrate resistant (ACP5); fascin homolog 1 actin-bundling protein (FSCN1); homeobox A1 (HOXA1); heat shock transcription factor 1 (HSF1); NDC80 homolog kinetochore complex component (NDC80); v-set and immunoglobulin domain containing 4 (VSIG4)	A study in patient tissue, mice and cell culture suggests ACP5, FSCN1, HOXA1, HSF1, NDC80 and VSIG4 may provide targets or biomarkers for metastatic melanoma. In melanoma cells, overexpression of each of those proteins increased invasiveness compared with overexpression of a control protein. In tumor tissue from melanoma patients, the targets were more highly expressed in malignant or metastatic tissue than in benign or primary tissue. Next steps include additional biological and functional studies of the identified genes.	Patent application filed covering therapeutic and diagnostic applications; licensed to Metamark Genetics Inc.	Scott, K.L. <i>et al. Cancer Cell</i> ; published online July 12, 2011; doi:10.1016/j.ccr.2011.05.025 Contact: Lynda Chin, Dana-Farber Cancer Institute, Boston, Mass. e-mail: lynda_chin@dfci.harvard.edu
SciBX 4(29); doi:10.1038/scibx.2011.825 Published online July 28, 2011				